Details

Autor(en) / Beteiligte

• Cao, Xinxin
• Li, Jian
• Zhang, Wei
• Duan, Minghui
• Zhu, Tienan
• Han, Bing
• Zhuang, Junling
• Cai, Huacong
• Chen, Miao
• Zhou, Daobin

Titel

Safety of polyethylene glycol conjugated L-asparaginase in patients with acute lymphoblastic leukemia and T cell non-Hodgkin lymphoma

Ist Teil von

• Zhōnghuá xuèyèxué zázhì, 2015-03, Vol.36 (3), p.177-180

Ort / Verlag

China

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• To evaluate the safety of polyethylene glycol conjugated L-asparaginase (PEG-Asp) for patients with adult acute lymphoblastic leukemia (ALL) and T cell non-Hodgkin lymphoma (T-NHL). A retrospective analysis was conducted on the clinical data of 101 young patients (≤40 years old) with ALL and T-NHL, diagnosed at Peking Union Medical College Hospital between January 2012 and June 2014. A total of 480 doses of PEG-Asp were administered in 44 cases with ALL and 57 patients with T-NHL. Only one patient (0.2%) experienced mild allergic reaction. Other grade 3 or 4 toxicities of non-hematologic effects included low level of fibrogen (6.4%), elevated ALT (4.4%), blood glucose (2.3%), and triglyceridemia (2.3%), decreased albumin (0.8%) and elevated amylase (0.2%). Furthermore, 5 cases (1.0%) developed venous thrombosis, 9 cases (1.9%) hemorrage, 1 patient (0.2%) non-necrosis pancretitis. The risk of allergic reaction incurred by PEG-Asp is very low. It can be used safely in ALL and T-NHL. Coagulation status should be